With Covid rev­enues falling, Pfiz­er lays out growth plans and pos­si­ble cost cuts

As the Pfiz­er be­he­moth con­tin­ues chug­ging along post-pan­dem­ic, the drug­mak­er is start­ing to clar­i­fy how its Covid-19 prof­its will turn in­to fu­ture growth.

For the first time Tues­day morn­ing, Pfiz­er broke down de­tailed growth ex­pec­ta­tions from its slew of ac­qui­si­tions made over the last year and a half. By 2030, Pfiz­er set a goal for at least $10 bil­lion in Seagen-re­lat­ed rev­enue. It ex­pects an­oth­er $10.5 bil­lion out of its deals for Bio­haven, Are­na, Glob­al Blood Ther­a­peu­tics and Re­Vi­ral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER